CA3071192A1 - Compositions de bucillamine a liberation modifiee, kits et methodes pour traiter la cystinurie, l'arthrite, la goutte et autres troubles apparentes - Google Patents

Compositions de bucillamine a liberation modifiee, kits et methodes pour traiter la cystinurie, l'arthrite, la goutte et autres troubles apparentes Download PDF

Info

Publication number
CA3071192A1
CA3071192A1 CA3071192A CA3071192A CA3071192A1 CA 3071192 A1 CA3071192 A1 CA 3071192A1 CA 3071192 A CA3071192 A CA 3071192A CA 3071192 A CA3071192 A CA 3071192A CA 3071192 A1 CA3071192 A1 CA 3071192A1
Authority
CA
Canada
Prior art keywords
bucillamine
hours
differently
composition
time point
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3071192A
Other languages
English (en)
Inventor
Patrick REICHENBERGER
Artem ZYKOVICH
Wolfgang Richter
Original Assignee
AltiBio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AltiBio Inc filed Critical AltiBio Inc
Publication of CA3071192A1 publication Critical patent/CA3071192A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des méthodes, des compositions, des dispositifs et des kits pour le traitement de la cystinurie et de troubles apparentés, de la bucillamine étant administrée à un patient selon une stratégie de libération modifiée qui fait que de la bucillamine est libérée, de préférence dans l'estomac, par impulsions répétées, judicieusement espacées dans le temps, pour obtenir des pics de concentration plasmatique plus bas de bucillamine totale, mais des concentrations urinaires toujours plus élevées du médicament libre, en vue de la liaison de la cystine. En particulier, l'utilisation des présents systèmes et formulations à libération modifiée réduit les effets secondaires de la bucillamine et permet d'obtenir une bonne efficacité avec des administrations moins fréquentes et/ou un dosage inférieur par rapport aux formes à libération immédiate. Les présentes stratégies peuvent également être utilisées dans le traitement de maladies inflammatoires, telles que la polyarthrite rhumatoïde ou la goutte, où de la bucillamine est administrée selon une stratégie de libération modifiée différente qui fait que de la bucillamine est libérée par des impulsions plus rapprochées, à nouveau de préférence dans l'estomac, pour fournir des pics de concentration sanguine de bucillamine totale plus bas, mais des concentrations sanguines plus élevées et plus stables du médicament non lié, ce qui améliore sa disponibilité dans le traitement de telles maladies.
CA3071192A 2017-07-25 2018-07-25 Compositions de bucillamine a liberation modifiee, kits et methodes pour traiter la cystinurie, l'arthrite, la goutte et autres troubles apparentes Pending CA3071192A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762536771P 2017-07-25 2017-07-25
US62/536,771 2017-07-25
PCT/US2018/043698 WO2019023346A1 (fr) 2017-07-25 2018-07-25 Compositions de bucillamine à libération modifiée, kits et méthodes pour traiter la cystinurie, l'arthrite, la goutte et autres troubles apparentés

Publications (1)

Publication Number Publication Date
CA3071192A1 true CA3071192A1 (fr) 2019-01-31

Family

ID=65041341

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3071192A Pending CA3071192A1 (fr) 2017-07-25 2018-07-25 Compositions de bucillamine a liberation modifiee, kits et methodes pour traiter la cystinurie, l'arthrite, la goutte et autres troubles apparentes

Country Status (4)

Country Link
US (1) US20210154161A1 (fr)
EP (1) EP3658130A4 (fr)
CA (1) CA3071192A1 (fr)
WO (1) WO2019023346A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3192658A1 (fr) * 2020-09-16 2022-03-24 Eric Gustin HASSENPFLUG Dispositif d'administration de medicament par voie orale avec bande d'expansion
AU2022210426A1 (en) * 2021-01-19 2023-08-24 Nortiva Bio, Inc. Gastric residence systems for administration of risperidone

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2814033B2 (ja) * 1992-01-10 1998-10-22 参天製薬株式会社 シスチン尿症治療剤
US6025393A (en) * 1995-09-25 2000-02-15 Santen Pharmaceutical Co., Ltd. Method for treatment of inflammatory intestinal diseases
WO2007079082A2 (fr) * 2005-12-30 2007-07-12 Advancis Pharmaceutical Corporation Systeme gastrique a impulsions de liberation pour l'administration de medicaments
WO2008148798A2 (fr) * 2007-06-04 2008-12-11 Egalet A/S Compositions pharmaceutiques à libération contrôlée pour un effet prolongé
AU2017235631B2 (en) * 2016-03-17 2023-03-02 Thiogenesis Therapeutics, Inc. Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders

Also Published As

Publication number Publication date
EP3658130A1 (fr) 2020-06-03
EP3658130A4 (fr) 2021-04-21
WO2019023346A1 (fr) 2019-01-31
US20210154161A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
Pinto Site-specific drug delivery systems within the gastro-intestinal tract: from the mouth to the colon
AU2023206140B2 (en) Pulsatile drug delivery system for treating morning akinesia
ES2260253T3 (es) Composicion farmaceutica oral de liberacion controlada y absorcion prolongada.
ES2649063T3 (es) Formulaciones farmacéuticas que contienen rifaximina, procedimientos para su obtención y método de tratamiento de la enfermedad intestinal
CA2879282C (fr) Systeme d'administration pharmacologique a retention gastrique
MXPA03011096A (es) Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna.
CZ2003199A3 (cs) Rychle expandující kompozice pro řízené uvolňování léčiva a retenci léčiva v žaludku a lékové formy obsahující tuto kompozici
CN101287443B (zh) pH控制的脉冲释放系统、其制备方法和用途
US20180078503A1 (en) Gastro-retentive drug delivery system
JP2008540437A (ja) キニーネを含有する制御放出調合剤
ES2336215T3 (es) Composiciones farmaceuticas de modafinil con liberacion modificada.
JP2022179727A (ja) リナクロチドの改変または標的放出製剤
AU2018285927B2 (en) Modified-release tiopronin compositions, kits and methods for treating cystinuria and related disorders
KR20140121394A (ko) 아캄프로세이트 제제, 그것의 사용 방법, 및 그것을 포함하는 조합
US20210154161A1 (en) Modified-release bucillamine compositions, kits, and methods for treating cystinuria, arthritis, gout, and related disorders
WO2004024128A2 (fr) Composition pharmaceutique a liberation modifiee
TW200800155A (en) Gastric retentive gabapentin dosage forms and methods for using same
US20130078287A1 (en) Pharmaceutical compositions of ibuprofen and an h2 receptor antagonist
CN113840595A (zh) 基质组合物，其包含(S)-5-苄基-N-(5-甲基-4-氧代-2,3,4,5-四氢苯并[b][1,4]氧氮杂环庚三烯-3-基)-4H-1,2,4-三唑-3-甲酰胺

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220929

EEER Examination request

Effective date: 20220929

EEER Examination request

Effective date: 20220929

EEER Examination request

Effective date: 20220929